← All indications
Lymphoma, T-Cell
A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.
Subtype terms (5)
More specific conditions that are subtypes of Lymphoma, T-Cell in the MeSH hierarchy.
- Enteropathy-Associated T-Cell Lymphoma
31 drugs (22 approved, 9 experimental)
- Lymphoma, Extranodal NK-T-Cell
58 drugs (37 approved, 21 experimental)
- Lymphoma, Large-Cell, Anaplastic
154 drugs (94 approved, 60 experimental)
- Lymphoma, T-Cell, Cutaneous
85 drugs (48 approved, 37 experimental)
- Lymphoma, T-Cell, Peripheral
170 drugs (91 approved, 79 experimental)
Drugs by status
Approved for this indication (6)
Phase 4 trials (25)
Phase 3 trials (22)
Phase 2 trials (134)
- allopurinol
- thalidomide
- decitabine
- methylprednisolone
- tioguanine
- 7-hydroxystaurosporine
- resimmune
- anlotinib
- aldoxorubicin
- amifostine
- aminolevulinic acid
- astx660
- avelumab
- olaparib
- sorafenib
- venetoclax
- calaspargase pegol
- irinotecan
- carfilzomib
- clofarabine
- nelarabine
- doxycycline
- selinexor
- durvalumab
- duvelisib
- enzastaurin
- obinutuzumab
- tacrolimus
- paclitaxel
- bone marrow derived mesenchymal stem cells
- +104 more
Phase 1 trials (76)
- fau
- dexrazoxane
- afm13
- allogeneic natural killer cells
- alvespimycin
- cilengitide
- devimistat
- polatuzumab vedotin
- entinostat
- genetically engineered lymphocyte therapy
- imatinib
- ar-42
- in111 anti-cd45 monoclonal antibody bc8
- medi-570
- methoxyamine
- morab-004
- mrg-106
- palbociclib
- sunitinib
- interleukin-15
- ro4929097
- rp6530
- sapanisertib
- siplizumab
- bevacizumab
- tak-659
- tanespimycin
- tetrahydrouridine
- triapine
- volasertib
- +46 more
Organizations
Organization Involved with Phase 4 Indications (28)
- Ligand Pharmaceuticals
- Eisai
- Bausch Health Companies
- Mallinckrodt
- Mundipharma
- National Cancer Institute (NCI)
- Huazhong University of Science and Technology
- University of Pittsburgh
- Boston University
- Case Western Reserve University
- Polish Lymphoma Research Group
- Qingdao University
- Shandong Provincial Hospital
- Shanxi Medical University
- Tufts University
- Wuhan University
- Yale University
- Zhengzhou University
- Vanderbilt University
- University of Minnesota
- Jiao Tong University
- National Taiwan University
- Rush University
- The University of Hong Kong
- University of Texas at Houston
- Henan Medical University
- Guizhou Medical University
- Xinyang Central Hospital
Organization Involved with Phase 3 Indications (31)
- Spectrum Pharmaceuticals
- Seattle Genetics
- Celgene
- Millennium Pharmaceuticals
- Emergent BioSolutions
- Genmab
- Novartis
- Elorac, Inc.
- Kyowa Hakko Kirin
- Portola Pharmaceuticals
- Soligenix
- Aarhus University
- German High-Grade Non-Hodgkin's Lymphoma Study Group
- French Innovative Leukemia Organisation
- Institut Bergonié
- Saitama Medical University
- The Lymphoma Academic Research Organisation
- Columbia University
- Fudan University
- Nordic Lymphoma Group
- Peking University
- CHU Henri Mondor
- Southern Medical University
- Tianjin Medical University
- European Organisation for Research and Treatment of Cancer
- Sun Yat-Sen University
- University of Goettingen
- University of Grenoble
- People's Liberation Army of China
- Chinese Academy of Medical Sciences
- +1 more
Organization Involved with Phase 2 Indications (229)
- 4SC AG
- Celimmune
- Galderma
- AbbVie
- Gloucester Pharmaceuticals
- Takeda
- Bristol-Myers Squibb
- BioCryst
- Amgen
- Roche
- AstraZeneca
- Merck
- Eli Lilly
- Merck KGaA
- Genzyme
- Pfizer
- Tibotec
- Angimmune LLC
- Asana BioSciences
- Bayer
- BeOne Medicines
- CerRx, Inc.
- Cyclacel Pharmaceuticals, Inc.
- GWT-TUD GmbH
- Hengrui Therapeutics, Inc.
- HUYA Bioscience International
- Innate Pharma
- Innovent Biologics (Suzhou) Co. Ltd.
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Karyopharm Therapeutics Inc
- +199 more
Organization Involved with Phase 1 Indications (38)
- PPD
- ADC Therapeutics SARL
- Aptevo Therapeutics
- Cephalon
- Morphotek
- Pharmacyclics
- Arno Therapeutics
- Bio-Path Holdings, Inc.
- Corvus Pharmaceuticals, Inc.
- Infinity Pharmaceuticals, Inc.
- Leadiant Biosciences, Inc.
- Therapeutics, Inc.
- Chipscreen Biosciences, Ltd.
- Tessa Therapeutics
- Translational Drug Development
- Johns Hopkins University
- Ludwig Institute for Cancer Research
- Nevada Cancer Institute
- University of Leeds
- University of Maryland
- University of Cologne
- SCRI Development Innovations
- Department of Veteran Affairs
- The Leukemia and Lymphoma Society
- Damon Runyon Cancer Research Foundation
- Synex Consulting Korea Ltd.
- Veristat, Inc.
- CLL Topics
- Antengene Corporation
- CRISPR Therapeutics
- +8 more
Organization Involved with Other Experimental Indications (4)